Drug formulation directly affects tablet manufacturing performance by determining how well a powder blend compresses, how consistently tablets release their active ingredient, and how stable the final product remains over time. The physical and chemical properties of the formulation govern every downstream manufacturing step, from blending and granulation through to compression and coating. The questions below unpack the key formulation variables that pharmaceutical researchers and process scientists need to understand before moving from bench to production scale.
What properties of a drug formulation influence tablet compression?
The compressibility, flowability, and cohesive strength of a powder blend are the primary formulation properties that govern tablet compression performance. When these properties are poorly matched to the compression process, the result is inconsistent tablet weight, hardness variation, and high rejection rates on the press.
Compressibility refers to the ability of a powder to reduce in volume under applied force and form a coherent compact. This depends on the particle size distribution, particle shape, and the plastic or brittle deformation behaviour of both the active pharmaceutical ingredient and its excipients. Poorly compressible actives often require the addition of binders or the use of granulation to improve bonding.
Flowability is equally critical. A blend that does not flow uniformly into the die cavity will produce tablets with significant weight variation. Bulk density, angle of repose, and Carr index are standard measurements used to characterise flow before compression trials begin.
Lubricant concentration also plays a significant role. Magnesium stearate, for example, reduces friction between the tablet and die wall, but over-lubrication weakens inter-particle bonding and reduces tablet tensile strength. Achieving the right balance requires careful evaluation during formulation development.
How does excipient selection affect tablet dissolution and bioavailability?
Excipient selection directly shapes the dissolution rate of a tablet and, by extension, the bioavailability of the active ingredient. Excipients are not inert carriers: they actively modulate how quickly and completely the tablet disintegrates and how the active substance is released into solution.
Disintegrants such as croscarmellose sodium or sodium starch glycolate absorb water rapidly and cause the tablet matrix to break apart, accelerating dissolution. The type and concentration of disintegrant chosen will determine whether a formulation achieves immediate, delayed, or extended release behaviour.
Binders affect the porosity of the tablet matrix. A highly compacted, low-porosity tablet may dissolve slowly regardless of disintegrant choice because water penetration is limited. Solubilisers and surfactants can be incorporated into the formulation to improve wetting of poorly water-soluble actives, which is a common challenge in formulation development for compounds with low aqueous solubility.
Filler selection matters too. Soluble fillers such as lactose dissolve rapidly and contribute to faster disintegration, while insoluble fillers like microcrystalline cellulose provide structural integrity but may slow water ingress depending on the matrix density.
Why do formulation changes cause tablet defects during manufacturing?
Formulation changes alter the mechanical and chemical behaviour of the powder blend, which disrupts the balance of forces during compression and can introduce defects such as capping, lamination, sticking, and picking. Even small changes in excipient grade or particle size can have significant downstream consequences.
Capping and lamination occur when the tablet separates horizontally during or after ejection from the die. These defects are typically linked to insufficient binding, elastic recovery of the compact, or excessive compression speed relative to the deformation characteristics of the blend. A change in binder type or concentration is a common trigger.
Sticking and picking happen when the tablet surface adheres to the punch face. This is often caused by formulations with high moisture content, low melting point actives, or insufficient lubrication. A change in the source or grade of a lubricant excipient can shift the lubrication balance enough to cause sticking at scale.
Understanding why changes cause defects requires a systematic approach to formulation characterisation. Each variable (particle size, moisture level, excipient grade, blend time) should be treated as a potential source of variability and evaluated before any change is introduced into a manufacturing process.
How does granulation method choice affect manufacturing performance?
The granulation method determines the physical structure of the granules entering the compression step, which in turn controls flowability, compressibility, and dissolution behaviour. Wet granulation, dry granulation, and direct compression each produce granules with distinct properties that suit different formulation types.
Wet granulation uses a liquid binder to agglomerate fine particles into larger, denser granules. This improves flowability and compressibility significantly, making it well suited to high-dose actives or poorly flowing powders. However, the process introduces moisture and heat, which can be problematic for moisture-sensitive or thermolabile compounds.
Dry granulation, achieved through roller compaction, avoids liquid entirely. It is preferred for moisture-sensitive actives and produces granules with good flow and acceptable compressibility, though the process can alter particle size distribution in ways that affect dissolution if not carefully controlled.
Direct compression bypasses granulation altogether and requires a blend that already has adequate flow and compressibility. It is the simplest and most cost-effective approach when the active and excipients are compatible with direct compression grades. The choice of granulation method is one of the earliest and most consequential decisions in formulation development, as it defines the processing constraints for all subsequent manufacturing steps.
What role does drug-excipient compatibility play in tablet stability?
Drug-excipient compatibility determines whether the active ingredient remains chemically stable throughout the tablet’s shelf life. Incompatible combinations can lead to degradation, discolouration, or loss of potency through reactions such as hydrolysis, oxidation, or Maillard reactions between amines and reducing sugars.
Compatibility screening is a standard part of early formulation development. Small-scale binary mixtures of the active with candidate excipients are stored under accelerated conditions (elevated temperature and humidity) and analysed over time for changes in appearance, assay, and impurity profile. This screening narrows the excipient selection before full formulation work begins.
Moisture is one of the most common drivers of instability. Hygroscopic excipients can raise the water activity within the tablet matrix, accelerating hydrolytic degradation of susceptible actives. Packaging selection, excipient drying, and moisture barrier coatings are all tools used to manage this risk.
Physical incompatibilities also matter. Some excipients can alter the polymorphic form of the active ingredient during processing or storage, which may change solubility and dissolution behaviour. Ensuring drug-excipient compatibility is therefore not only a stability requirement but also a bioavailability consideration.
How should formulation parameters be evaluated before scale-up?
Before scaling a tablet formulation from laboratory to pilot or production scale, a structured evaluation of critical formulation parameters is essential. This evaluation should confirm that the formulation behaves predictably under the mechanical and environmental conditions of larger-scale manufacturing equipment.
The following parameters are typically assessed during pre-scale-up evaluation:
- Blend uniformity: confirming that the active is distributed homogeneously throughout the powder blend at the intended batch size
- Compressibility profile: mapping tablet hardness and tensile strength across a range of compression forces to identify the optimal operating window
- Dissolution profile: verifying that the release rate meets specifications across multiple tablet hardness levels
- Moisture sensitivity: assessing how the blend responds to humidity variations typical of manufacturing environments
- Lubrication sensitivity: determining how robust the formulation is to variations in mixing time and lubricant concentration
Risk-based approaches such as design of experiments (DoE) are widely used in pharmaceutical manufacturing to map the interactions between formulation and process variables efficiently. This approach identifies which parameters have the greatest influence on critical quality attributes, allowing development teams to define a proven acceptable range before committing to full-scale production runs.
In GMP manufacturing environments, this pre-scale-up data forms part of the process understanding package required by regulatory authorities. Documenting formulation performance at each development stage supports both regulatory submissions and ongoing process control after commercialisation.
- Characterise the powder blend using compressibility, flowability, and particle size data
- Screen drug-excipient compatibility under accelerated conditions
- Select granulation method based on active properties and target dissolution profile
- Run compression trials across a range of forces and speeds to define the process window
- Confirm dissolution and stability performance before committing to pilot-scale batches
How ChemSPX supports pharmaceutical formulation and manufacturing research
For research teams and laboratory professionals in the Benelux working on tablet formulation and pharmaceutical manufacturing workflows, ChemSPX provides expert guidance and high-end instrumentation to support every stage of the development process. The ChemSPX team works directly with researchers and lab managers to advise on the right instruments for their specific application needs.
- Instrumentation for batch and flow synthesis, supporting formulation research from early-stage development through to scale-up
- Preparative and flash chromatography systems for purification workflows within pharmaceutical research environments
- IQ/OQ installation, validation, and calibration services aligned with GMP and GLP standards
- Application-level support from Sales Engineers and Product Specialists based in the Netherlands and Belgium
Whether you are evaluating new instrumentation for your formulation laboratory or looking for specialist support on an existing system, the ChemSPX team is ready to help. Contact ChemSPX to discuss your laboratory requirements with a specialist.
Frequently Asked Questions
What is the difference between a critical formulation parameter and a critical process parameter, and why does it matter?
A critical formulation parameter (CFP) is an intrinsic property of the formulation itself — such as binder concentration, particle size distribution, or lubricant level — that directly impacts a critical quality attribute like tablet hardness or dissolution rate. A critical process parameter (CPP), by contrast, relates to the manufacturing equipment settings, such as compression force or granulator impeller speed. The distinction matters because CFPs must be locked down during formulation development before process optimisation begins; attempting to compensate for a poorly designed formulation by adjusting process parameters alone typically leads to a narrow, fragile operating window that is difficult to maintain at production scale.
How do I know whether my formulation is robust enough to handle normal manufacturing variability?
Robustness is best assessed through a structured design of experiments (DoE) study in which key formulation variables — such as lubricant concentration, blend time, and moisture content — are deliberately varied within realistic ranges and their effect on critical quality attributes is measured. A robust formulation will show only minor, acceptable changes in tablet hardness, dissolution, and weight uniformity across these variations. If small changes in a single variable cause significant quality failures, that variable should be treated as a high-risk parameter requiring tighter in-process controls or reformulation before scale-up.
What are the most common mistakes made when transferring a tablet formulation from lab scale to pilot scale?
The most frequent pitfall is assuming that a formulation that performs well on a small-scale press will behave identically on larger rotary tablet presses, where dwell times, compression speeds, and die filling dynamics differ considerably. Other common mistakes include failing to re-characterise blend uniformity at the larger batch size, underestimating the impact of environmental humidity in the manufacturing suite on moisture-sensitive blends, and not re-evaluating lubrication sensitivity when mixing times change with larger blender volumes. Running a structured pre-scale-up evaluation, as outlined in the post, is the most reliable way to identify and resolve these issues before committing to pilot batches.
Can excipient supplier changes affect tablet performance even if the excipient grade stays the same?
Yes, and this is a well-documented challenge in pharmaceutical manufacturing. Even when the nominal grade and specification of an excipient remain unchanged, differences between suppliers in particle size distribution, moisture content, surface area, and impurity profile can meaningfully alter blend flowability, compressibility, and drug-excipient interactions. Regulatory guidelines require that any change in excipient supplier be assessed for potential impact on the formulation, and in many cases a comparability study or updated dissolution testing is needed. Building supplier qualification and incoming material testing into your quality system is the best defence against this source of variability.
How should I approach formulation development for a poorly water-soluble active ingredient?
Poorly water-soluble actives — those falling into BCS Class II or IV — require a solubility enhancement strategy as a foundational part of formulation design. Common approaches include particle size reduction through micronisation or nanonisation, amorphous solid dispersion using polymeric carriers, co-precipitation, or the use of solubilising excipients such as surfactants and cyclodextrins. The choice of strategy depends on the physicochemical properties of the molecule, the target dose, and the intended release profile. Importantly, any solubility enhancement technique also needs to be evaluated for physical and chemical stability, since amorphous forms and fine particles are inherently more energetically unstable than their crystalline counterparts.
At what stage of development should drug-excipient compatibility screening be completed?
Compatibility screening should be completed as early as possible — ideally during pre-formulation, before full formulation work begins — so that incompatible excipients are eliminated before resources are invested in development batches. The standard approach involves preparing binary and ternary mixtures of the active with candidate excipients, storing them under accelerated conditions (typically 40°C/75% RH for four to eight weeks), and analysing for changes in assay, impurity profile, and physical appearance. Completing this work early not only protects product quality but also reduces the risk of costly reformulation later in development when regulatory timelines are more constrained.
What analytical tools are most useful for characterising a powder blend before compression trials?
A core set of analytical measurements should be completed before any compression trial begins: bulk and tapped density (to calculate Carr index and Hausner ratio as flow indicators), angle of repose, particle size distribution by laser diffraction, and moisture content by Karl Fischer titration or loss on drying. For more detailed compressibility characterisation, compaction simulators or instrumented tablet presses can generate compressibility and tabletability profiles across a range of compression forces, which are invaluable for defining the process window before moving to full-scale press trials. Blend uniformity testing by stratified sampling is also essential to confirm homogeneous active distribution before compression begins.
Related Articles
- What is the difference between angle of repose and Carr's index?
- What causes variability in tablet dissolution profiles?
- How does powder segregation affect content uniformity in tablets?
- How do you scale up a chromatography process from lab to production?
- How does chromatography work to separate compounds?
This content was generated with the help of AI and it may contain mistakes